Clinical trial
Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic…
NCT00323063 · Rutgers, The State University of New Jersey, Other · Terminated
Key facts
| NCT number | NCT00323063 |
|---|---|
| Title | Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer |
| Official title | Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate Versus Gemcitabine Alone in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer |
| Lead sponsor | Rutgers, The State University of New Jersey, Other |
| Collaborators | National Cancer Institute (NCI) NIH Novartis Pharmaceuticals Industry Rutgers Cancer Institute of New Jersey |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride, imatinib mesylate |
| Enrollment | 49 |
| Start date | May 1, 2006 |
| Primary completion | Apr 15, 2011 |
| Completion | Jun 20, 2016 |
| First posted | May 9, 2006 |
| Last update posted | Mar 29, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: